Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Immunochemotherapy using the antitumor polysaccharide Sizofiran (SPG), an extract from the culture broth of Schizophyllum, was prescribed randomly for unresectable or resectable gastric cancer patients. In case of unresectable cases, the SPG group (treated by SPG plus tegafur--F method--or 5-FU combined with MMC--MF method--) survived longer (p = 0.009 in the MF method and p = 0.003 in the F method) than did the control group (chemotherapy only). Concerning a treatment regimen for resectable cases, all patients were given 0.4mg/kg and 0.2mg/kg of MMC on the day of surgery and the next day, respectively. Oral tegafur was initiated on the 14th postoperative day and was continued as long as possible. In the SPG group, SPG was administered intramuscularly 40mg/week concurrently with the start of oral tegafur and was continued as long as possible. Although the overall survival rates for 5 years did not differ between both groups, the 5-year survival rate for stage III in the SPG group was superior to the findings for stage III in the control (p = 0.0105).
 ...
PMID:[Clinical efficacies of schizophyllan (SPG) on advanced gastric cancer]. 253 Dec 70

140 patients with advanced gastric cancer confirmed by pathology were treated by UFT (Uracil, FT-207) and mitomycin C (MMC) from Sept. 1985 to June 1987. All the patients received UFT #3 T. i. d. to a total dose of 30 g. Mitomycin C, 8-20 mg i. v. Q. wk was given to a total dose of 48-60 mg. Of the 140 patients, 65 had cancer of cardia, 36 cancer of gastric body, and 39 cancer of gastric antrum. There were 125 males and 15 females. The ages ranged from 30 to 80 years. In this series, CR was 10.0% and PR 44.3% with total remission rate of 54.3% (76/140). Thirty-four patients receiving UFT alone as control had a response rate of 26.5%. The response rate was higher in patients treated with UFTM than those with UFT alone. The median remission was 4 months. That main side effects were leukopenia and thrombocytopenia. The results showed that combination chemotherapy (UFTM) was valid in treating advanced gastric cancer.
 ...
PMID:[Combined UFTM for 140 patients with advanced gastric cancer]. 255 64

The survival curves of MGc80-3 cells exposed for 24 hr to various concentrations of 10 anticancer drugs were obtained by means of colony-forming assay. Comparison of drug doses required to reduce cell survival by 90% (ID90) with the clinically achievable peak plasma drug concentration (PPC) showed that MMC, ADM, and 5-Fu had strong cytotoxicity (PPC/ID90 = 18-36), whilst the other drugs were less effective (PPC/ID90 less than or equal to 11). The fact that MMC, ADM, and 5-Fu are most effective in the treatment of gastric cancer suggests that the cell line MGc 80-3 may still retain its original drug sensitivity which is consistent with that noted in clinical gastric cancer. This cell line could be useful in screening for new compounds with activity against this disease.
 ...
PMID:[Chemosensitivity of MGc 80-3 human gastric adenocarcinoma cells and its clinical significance]. 255 35

This study was carried out to evaluate whether the preoperative levels of serum glycoproteins (CEA, SCC, TPA, IAP, ACT, ASP and sialic acid) and HLA antigens (class I and II) could be potential aids in the selection of suitable gastric and esophageal cancer patients for postoperative adjuvant immunotherapy of PSK. Gastric cancer patients underwent gastrectomy and received postoperative adjuvant chemotherapy (MMC, FT and ADR) with or without PSK. One hundred and forty esophageal cancer patients in cooperative study groups (organizing chairman; Dr. Hiroshi Satoh) underwent esophagectomy and received postoperative adjuvant radiotherapy and chemotherapy (FT, BLM) with or without PSK. The efficacy of PSK was recognized in the patients with normal levels of all glycoproteins in gastric cancer, and with normal levels of CEA or SCC or TPA and abnormal levels of one or more APRs in both gastric and esophageal cancer, and with positive HLA-B40 antigen. The combination of tumor-associated factors, such as CEA, SCC and TPA and various non-specific reactants such as APRs was useful as a prognostic indicator. In addition, some of HLA antigens were also valuable. The pretreatment levels of glycoproteins and HLA antigens have potential aids in the selection of patients with gastric and esophageal cancer for PSK treatment.
 ...
PMID:[Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators]. 258 37

The murine monoclonal antibody (MoAb)3H11 against human gastric cancer was purified with affinity column and conjugated with Mitomycin C (MMC). The binding activity of MoAb in the conjugate retained more than 90% of the original MoAb 3H11 when the molar ratios of MMC to 3H11 was 7-8:1. The killing rate of 3H11-MMC conjugate on human gastric cancer cells BGC 823 was increased significantly than that of free MMC in vitro. The selective cytotoxicity was verified with the following results: (1) the cytotoxicity of the conjugate was much higher than that of normal mouse IgG (nMuIgG) conjugated with MMC; (2) when breast cancer cells MCF-7 was used as target cells instead of BGC 823 cells, much lower cytotoxicity of the conjugate was observed; (3) the cytotoxicity of the conjugate on BGC823 cells could be blocked when the target cells was preincubated with MoAb 3H11, but not with MoAb 3G9 which did combine with BGC823 cells at binding sites different from MoAb 3H11. Nude mice were inoculated with BGC823 cells as a model of gastric cancer and treated with conjugate 3H11-MMC, nMuIgG-MMC, MMC or PBS (ip). It was shown that the time of tumor formation and the rate of tumor growth in 3H11-MMC conjugate treated animals were significantly different from that in control groups. The rate of inhibition of tumor weights was 60.4% for the conjugate 3H11-MMC treated group which was significantly higher than for other groups.
 ...
PMID:[The selective cytotoxicity of monoclonal antibody conjugated with mitomycin C on human gastric cancer cells]. 261 75

Fifty-seven patients with non-resectable liver metastases (31 from colon cancer, 26 from gastric cancer) received 5-FU, ADR, MMC combined hepatic arterial infusion therapy. (FAMia: 5-FU 334 mg/m2 qw, ADR 20 mg/m2 q4w, MMC 2.7 mg/m2 q2w; in colon cancer, 5-FU 167 mg/m2/day continuously for 3 months and then 334 mg/m2 qw). Myelo-suppression, hepatic arterial occlusion, gastroduodenal toxicity and elevation of biliary enzyme were observed at 29%, 39%, 32% and 13% in colon cancer, respectively, and at 35%, 8%, 0% and 0% in gastric cancer, respectively. Response rates evaluated by CT-scan were 63% (1 CR + 18 PR/30) in colon cancer and 79% (4 CR + 15 PR/24) in gastric cancer. Overall median survival was 352 days in colon cancer and 449 days in gastric cancer. Concerning background factors, the response rate in the well-differentiated type of colon cancer was significantly higher than in the moderately differentiated type, and significantly low in poorly differentiated medullary type gastric cancer. The existence of extra-hepatic lesions was the most important factor in survival in both cancers. [colon cancer: (-) 740 days vs (+) 267 days; gastric cancer: (-) 517 days vs (+) 245 days]. In conclusion, this therapy yields favorable direct effects on liver metastases from colon and gastric cancer without major side-effects and complications, but effective therapy of extrahepatic lesions is required for longer survival. Now, to release colon cancer patients from restrictions of continuous infusion pumps, a phase I study of weekly high dose 5-FU HAI therapy is under way.
 ...
PMID:[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. 278 85

Four primary liver tumors and 19 secondary ones (8 gastric, 8 colorectal, 2 esophageal and 1 gall bladder cancer) were treated by intra-arterial infusion chemotherapy intermittently using implantable reservoir. Drugs used in this series were 5-Fluorouracil, Mitomycin C, Adriamycin, and Cis-platinum. They were infused every 2 weeks for outpatients. The antitumor efficacy was evaluated in terms of tumor regression measured by CT scan. The toxicity was slight and temporary. The total response rate was 23.1%, 50% survival period was 7 months, and 1-year survival rate was 24.2%. The response rate was 33.3%, and the 50% survival period was 7 months for 8 gastric cancer patients with liver metastasis. The result was not good, and we must improve the criteria of indication and devise a regimen. But the implantable drug delivery system has made it possible to lengthen the time that patients may stay home and assure good quality of life because of the freedom of movement, normal physical appearance, protection from infection, and reduction of mental burden, due to subcutaneous placement.
 ...
PMID:[Arterial infusion cancer chemotherapy in liver tumor using implantable reservoir]. 278 8

During the period from June 1973 to December 1978, 338 patients with advanced gastric cancer were treated in our hospital. By retrospective grouping, 142 out of 265 patients with tumor resected received postoperative adjuvant chemotherapy (MMC + 5FU + Ara-C), 123 operated alone were taken for comparison. These two groups were similar in: age, sex, location of tumor, mode of resection, histological type, clinical stage and follow-up rate. The results indicated that the 1, 3 and 5 year survival rates of the combined group were much higher than those of the operation only group. Further analysis showed that the supplementary chemotherapy was particularly valid in stages III and IV. In stage III patients, the 5 year survival rate was increased by 27.8%. In stage IV patients, the 3 and 5 year survival rates of the combined group were 16.3% and 9.8% but none survived over 3 years in the operation only group. The authors believe that postoperative adjuvant chemotherapy plays an important role in controlling the micrometastatic and residual cancer foci.
 ...
PMID:[Long-term results of an operation alone and postoperative adjuvant chemotherapy in advanced gastric cancer--report of 265 patients]. 283 38

A retrospective study of 75 patients with advanced inoperable gastric cancers, referred to the National Cancer Center Hospital between 1962 and 1982, was performed. According to the Borrmann classification based on X ray findings, Type 1 was found in 3 patients, Type 2 in 5, Type 3 in 40, and Type 4 in 15. Twelve patients could not be classified. The histological type was papillary adenocarcinoma in 7 patients, tubular adenocarcinoma in 23, mucinous carcinoma in 6, poorly differentiated adenocarcinoma in 14, signet ring cell carcinoma in 12 and others in 13. The site of remote metastasis in 19 patients was Virchow's lymph node in 8 patients, Douglas pouch in 3, liver and lung in 2 each and others in 4. All patients were treated by a either telecobalt 60 unit or a linear accelerator using 6 Mv photon and the total dose to primary lesion was 4000 cGy in 5 weeks to 7000 cGy in 8-9 weeks. Complete response (CR) was achieved in 6 patients or 8.0%, partial response (PR) in 46 or 61.3%, and no change (NC) in 23 or 30.7%. The response rate based on the sum of CR and PR was about 70%. The 50% survival period in months was 26.5, 7.3, and 3.2, respectively for patients with CR, PR, and NC. For the response of advanced gastric cancer to chemotherapy in the National Cancer Center Hospital, the combined use of UFT and Mitomycin C gave the highest rate, 46%. As for as local response is concerned, the response rate to radiation was 70%, a better result than that of chemotherapy alone.
 ...
PMID:Radiation therapy for advanced gastric cancer. 283 38

Cytotoxic effects of allyl trisulfide (Alt, a synthetic chemical identical with one of the main active principles of garlic), 5 FU, MMC and DDP on SGC 7901 ( a moderately differentiated human gastric adenocarcinoma cell line) and MGC 803 (a poorly differentiated human gastric mucoadenocarcinoma cell line) had been reported before. In this paper, effects of repeated two doses of each drug and the combination of two drugs on these two cell lines were studied using relative clone-survival test. The inhibitory effects of Alt, MMC alone or combined on MGC tumor in nude mice were observed. No drug resistance was found when any one of the four agents at the same concentration were repeated twice separately at 60 hour interval in vitro. The cytotoxic effect of the repeated two doses was approximately equal to that of the single dose at double concentration. The in vitro test of combinations of two drugs showed that Alt plus MMC or 5 FU plus DDP had markedly synergistic effect on MGC cells; 5 FU plus DDP had markedly synergistic effect on SGC cells. The inhibition test on the growth of MGC tumor in nude mice indicated that the inhibition rates of Alt, MMC alone or combined were 58.3%, 86.3% and 84.3%. The systemic toxic effect of MMC alone was severe, whereas Alt alone or MMC plus Alt showed mild toxicity. For this reason, Alt plus MMC is recommended for clinical trials on poorly differentiated gastric cancer. In addition, for the comparison of in vitro test dose and clinical dose of each drug, the principle of clinical adult dose range (CADR) is proposed.
 ...
PMID:[Experimental chemotherapy of human gastric cancer cell lines in vitro and in nude mice]. 284 30


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>